Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

ABSTRACT:

Objective

Clozapine is the most effective antipsychotic for treatment refractory people with schizophrenia, yet many patients only partially respond. Accumulating preclinical and clinical data suggest benefits with minocycline. We tested adjunct minocycline to clozapine in a 10-week, double-blind, placebo-controlled trial. Primary outcomes tested were positive, and cognitive symptoms, while avolition, anxiety/depression, and negative symptoms were secondary outcomes.

Methods

Schizophrenia and schizoaffective participants (n = 52) with persistent positive symptoms were randomized to receive adjunct minocycline (100 mg oral capsule twice daily; n = 29) or placebo (n = 23).

Results

Brief Psychiatric Rating Scale (BPRS) psychosis factor (P = 0.098; effect size [ES], 0.39)

SUBMITTER: Kelly DL 

PROVIDER: S-EPMC4485552 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature